Compare CAR & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAR | DNLI |
|---|---|---|
| Founded | 1946 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.4B |
| IPO Year | 1998 | 2017 |
| Metric | CAR | DNLI |
|---|---|---|
| Price | $126.11 | $19.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 20 |
| Target Price | ★ $110.43 | $36.19 |
| AVG Volume (30 Days) | 402.1K | ★ 1.7M |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,652,000,000.00 | N/A |
| Revenue This Year | $0.09 | N/A |
| Revenue Next Year | $1.39 | $210.02 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $85.96 | $15.34 |
| 52 Week High | $847.70 | $27.30 |
| Indicator | CAR | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 65.64 | 51.25 |
| Support Level | $95.15 | $19.12 |
| Resistance Level | $127.83 | $20.84 |
| Average True Range (ATR) | 6.03 | 0.87 |
| MACD | 2.89 | 0.20 |
| Stochastic Oscillator | 90.18 | 42.17 |
Avis Budget Group Inc is a provider of mobility solutions through its three brands Avis, Budget and Zipcar, as well as several other brands, well recognized in their respective markets. Its brands offer a range of options, from car and truck rental to car sharing. The company operates in two reportable business segments: Americas - (i) vehicle rental operations in North America, South America, Central America and the Caribbean, (ii) car sharing operations in certain of these markets, and (iii) licensees in the areas in which do not operate directly. International - consisting of (i) vehicle rental operations in Europe, the Middle East, Africa, Asia and Australasia, (ii) car sharing operations in certain of these markets, and (iii) licensees in the areas in which do not operate directly.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.